Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can pressurized oxygen tame blood sugar spikes?

NCT ID NCT04261738

Knowledge-focused Sponsor: Legacy Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study asks whether a single session of hyperbaric oxygen therapy (HBOT) can lower blood sugar or change glucagon levels in people with type 1 or type 2 diabetes. Participants will undergo one HBOT session and one control session (sitting in a room at normal pressure), while their blood sugar is monitored continuously and through fingersticks. The trial also checks how well a continuous glucose monitor performs during HBOT. It's a small, early study focused on short-term effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hyperbaric oxygen therapy (HBOT) - breathing pure oxygen in a pressurized chamber
What this could lead to
If it works, this could point toward hyperbaric oxygen as a potential aid for blood sugar management in diabetes.
What could go wrong
This is a very small, early study (6 people) that only looks at short-term effects of a single session, so results may not apply broadly or lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6 people

The number who actually took part.

Started

Sep 2022

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of type 1 or type 2 diabetes * Willing to have 2 subcutaneous glucose monitors for 10 days * Willing to be NPO after midnight on the day of the study session * Willing to come to the hyperbaric facility on successive days (one control session and one hyperbaric treatment), spending approximately 3 hours in the facility on each day of testing * Willing to undergo multiple fingersticks on the days of testing * Willing to have a peripheral intravenous catheter placed for blood sampling * Willing to perform four daily fingerstick blood glucose checks throughout the study period Exclusion Criteria: * Contraindication to HBO2 as determined by the study investigator (e.g., pregnancy) * Previous treatment with HBO2 within 30 days of enrollment * Current use of CGM is not an exclusion, but participants must use study equipment during the study * Current use of an insulin pump * Known allergy to medical-grade adhesives * Extensive skin changes/disease that preclude wearing the sensor on normal skin (e.g. extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1 type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus, type 1 Diabetes mellitus, type 2

Contacts and locations

Locations

  • Legacy Emanuel Medical Center

    Portland, Oregon, 97227, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.